COST

1,015.89

+0.48%↑

PG

144.47

+0.42%↑

PM

168.74

-0.42%↓

PEP

154.97

+0.22%↑

FMX

122.22

+1.52%↑

COST

1,015.89

+0.48%↑

PG

144.47

+0.42%↑

PM

168.74

-0.42%↓

PEP

154.97

+0.22%↑

FMX

122.22

+1.52%↑

COST

1,015.89

+0.48%↑

PG

144.47

+0.42%↑

PM

168.74

-0.42%↓

PEP

154.97

+0.22%↑

FMX

122.22

+1.52%↑

COST

1,015.89

+0.48%↑

PG

144.47

+0.42%↑

PM

168.74

-0.42%↓

PEP

154.97

+0.22%↑

FMX

122.22

+1.52%↑

COST

1,015.89

+0.48%↑

PG

144.47

+0.42%↑

PM

168.74

-0.42%↓

PEP

154.97

+0.22%↑

FMX

122.22

+1.52%↑

Search

Lifecore Biomedical Inc

Open

BrancheKonsumgüter defensiv

5.23 3.16

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.2

Max

5.33

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.9M

-10M

Verkäufe

-5.3M

31M

Gewinnspanne

-32.116

Angestellte

400

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+26.81% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

10. Juni 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-81M

160M

Vorheriger Eröffnungskurs

2.07

Vorheriger Schlusskurs

5.23

Nachrichtenstimmung

By Acuity

50%

50%

61 / 131 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Mai 2026, 22:17 UTC

Ergebnisse

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4. Mai 2026, 23:47 UTC

Ergebnisse

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4. Mai 2026, 23:45 UTC

Ergebnisse

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4. Mai 2026, 23:45 UTC

Ergebnisse

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4. Mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4. Mai 2026, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Jim Beyer To Be Chief Executive of Combined Company

4. Mai 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4. Mai 2026, 22:42 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4. Mai 2026, 22:42 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4. Mai 2026, 22:41 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4. Mai 2026, 22:41 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4. Mai 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Shareholders to Own About 51% of Combined Company

4. Mai 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Board Unanimously Endorsed, Supported Deal

4. Mai 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Deal Unanimously Recommended by Vault Board

4. Mai 2026, 22:39 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4. Mai 2026, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Regis Resources to Acquire All Ordinary Shares in Vault

4. Mai 2026, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Regis Resources, Vault Minerals Agree to Merger of Equals

4. Mai 2026, 22:37 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4. Mai 2026, 22:26 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4. Mai 2026, 22:02 UTC

Ergebnisse

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4. Mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4. Mai 2026, 21:52 UTC

Ergebnisse

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4. Mai 2026, 21:50 UTC

Ergebnisse

Westpac: Some Sectors More Affected Than Others>WBC.AU

4. Mai 2026, 21:50 UTC

Ergebnisse

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4. Mai 2026, 21:49 UTC

Ergebnisse

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4. Mai 2026, 21:44 UTC

Ergebnisse

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4. Mai 2026, 21:44 UTC

Ergebnisse

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4. Mai 2026, 21:43 UTC

Ergebnisse

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4. Mai 2026, 21:41 UTC

Ergebnisse

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4. Mai 2026, 21:40 UTC

Ergebnisse

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer-Vergleich

Kursveränderung

Lifecore Biomedical Inc Prognose

Kursziel

By TipRanks

26.81% Vorteil

12-Monats-Prognose

Durchschnitt 6.67 USD  26.81%

Hoch 9 USD

Tief 5 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lifecore Biomedical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Stimmung

By Acuity

61 / 131 Ranking in Konsumgüter defensiv

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
help-icon Live chat